Roche Holding AG (0QQ6.IL)
| Previous close | 303.61 |
| YTD return | N/A |
| Expense ratio (net) | N/A |
| Category | N/A |
| Last cap gain | N/A |
| Morningstar rating | N/A |
| Morningstar risk rating | N/A |
| Sustainability rating | N/A |
| Net assets | N/A |
| Beta (5Y monthly) | N/A |
| Yield | N/A |
| 5y average return | N/A |
| Holdings turnover | N/A |
| Last dividend | N/A |
| Average for category | N/A |
| Inception date | N/A |
Globe Newswire[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
Group sales were up by 5%1 at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8% Group sales growth accelerated to 9% (7% in CHF) in the second quarter as the decline in COVID-19-related sales no longer had an impact on overall salesPharmaceuticals Division sales rose by 5% in the first half; strong growth of 8% in the base business2 excluding COVID-19 effect
Yahoo Finance UKStocks to watch this week: Tesla, Microsoft, Alphabet and Amazon
Earnings preview of key companies reporting this week and what to look out for.
Business WireNew Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
SOUTH SAN FRANCISCO, Calif., July 18, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively, the two leading causes of vision loss in adults with diabetes. Susvimo is the first and only refillable eye implant that provides continuous delivery of a custom
